GFH276 / GenFleet Therap - LARVOL DELTA

Pan-RAS(on) Inhibitors RMC-6236 and GFH276 With Omeprazole or Ensartinib in KRAS-mutant Lung Cancer Cells (IASLC-WCLC 2026) - "Our previous work showed that the combination of omeprazole plus tepotinib is active in KRAS-mutant G12C and non-G12C cell lines ( Rosell et al...The H23 and A549 (sotorasib-resistant) cells were sensitive to both Pan-RAS(ON) inhibitors with higher IC 50s...Finally, pretreatment with omeprazole plus Pan-RAS inhibitors suggests a potential to delay resistance. Like crizotinib, ensartinib has activity against ALK, ROS1, and MET, and additionally targets AXL; therefore, ensartinib warrants further investigation."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • AXL • CTNNB1 • KRAS • ROS1 • SQSTM1 • STAT3

Safety and efficacy of GFH276 monotherapy in previously treated RAS-mutated advanced solid tumors (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Metastases • Monotherapy • Oncology • Solid Tumor

A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Genfleet Therapeutics (Shanghai) Inc.

Monotherapy • New P2 trial • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • KRAS

GenFleet Therapeutics…is pleased to announce the initiation of a three-arm, parallel-controlled phase II study evaluating two novel combination regimens versus monotherapy of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, among pretreated KRAS G12D-mutant patients with locally advanced unresectable or metastatic pancreatic cancer (HKEXnews) - "The multicenter, open-label, randomized controlled study will be conducted across tens of clinical sites in the Chinese mainland; with Ruijin Hospital Affiliated to Shanghai Jiao Tong University's School of Medicine as the leading site. The two combination therapies include GFH375 plus GFS202A, the world’s first cachexia-targeted bispecific antibody (GDF15/IL-6 bispecific antibody), and GFH375 plus GFH276, a Pan RAS (ON) inhibitor."

New P2 trial • Pancreatic Cancer

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (clinicaltrials.gov) - P1/2 | N=222 | Not yet recruiting | Sponsor: Genfleet Therapeutics (Shanghai) Inc.

New P1/2 trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • KRAS • RAS

Preclinical evaluation of GFH276 monotherapy and combination therapy for RAS-mutant tumors (AACR 2026) - P1/2 | "Here we present a further pre-clinical assessment of GFH276 monotherapy and its rational combination with distinct therapeutic agents. BULB/c nude mice bearing CDX tumors harboring different KRAS mutations were used to determine the anti-tumor efficacy of GFH276 monotherapy or its combination with Cetuximab. GFH276 monotherapy was effective in mouse models harboring tumors originating from most common RAS-mutant cancers. GFH276 also showed synergistic effects with anti-EGFR mAb and immunotherapy. These results depict the promising therapeutic potential of GFH276 in broad indications via different application strategies."

Combination therapy • IO biomarker • Monotherapy • Preclinical • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Uterine Cancer • KRAS

GFH276: A molecular glue panRAS(on) inhibitor with broad spectrum anti-tumor activities (AACR 2025) - "Compared to SIIP-based KRAS G12C inhibitors Sotorasib, Adagrasib and Divarasib, GFH276 was not susceptible to upstream RTK-reactivation by EGF stimulation and remained effective against cell lines carrying second KRAS mutations or RTK alterations or with induced resistance to Sotorasib. GFH276 demonstrated strong therapeutic activities in tumors with activating RAS and RTK alterations. Encouraged by these promising results, we are advancing GFH276 into the Phase 1 clinical trial by conducting IND-enabling studies and the IND submission is planned in Q2 2025."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF • EGFR • FGFR2 • HRAS • KRAS • NRAS

GenFleet Therapeutics…is pleased to announce that the Company will exhibit preclinical research data of three compounds - GFH276 (non-degrading molecular glue), GFS784 (novel antibody-drug conjugate linking functional antibody with synergistic targeted payload) and GFH603 (molecular glue-like covalent allosteric activator) - at the poster presentation of the 2026 AACR Annual Meeting (HKEXnews)

Preclinical • Oncology

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=450 | Not yet recruiting | Sponsor: Genfleet Therapeutics (Shanghai) Inc.

New P1/2 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

FIRST PATIENT DOSED WITH GFH276, A MOLECULAR GLUE PAN RAS (ON) INHIBITOR, IN A PHASE I/II STUDY TREATING RAS-MUTANT CANCER PATIENTS (HKEXnews) - "The phase Ia trial of GFH276 will be conducted at approximately 10 investigational sites including the Sun Yat-sen University Cancer Center in southeastern China and Fudan University Shanghai Cancer Center."

Trial status • Solid Tumor